Screener
Collegium Pharmaceutical, Inc. COLL Nucynta IR — Product revenues, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:34 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053851
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Belbuca | $57,669 | $52,600 | $110,318 | $104,258 |
| Xtampza ER | 45,006 | 52,605 | 95,775 | 100,247 |
| Jornay PM | 46,058 | 32,626 | 84,951 | 61,165 |
| Nucynta IR | 14,356 | 26,501 | 40,434 | 53,918 |
| Nucynta ER | 15,723 | 19,946 | 33,957 | 39,632 |
| Azstarys | 12,910 | — | 12,910 | — |
| Symproic | 3,020 | 3,722 | 7,213 | 6,537 |
| Nucynta ER AG | 2,775 | — | 4,221 | — |
Item 1. Condensed Consolidated Financial Statements (Unaudited).
FAQ
- What is Collegium Pharmaceutical, Inc.'s nucynta IR — product revenues, net?
- Collegium Pharmaceutical, Inc. (COLL) reported nucynta IR — product revenues, net of $14.36M in Q2 2026.
- How has Collegium Pharmaceutical, Inc.'s nucynta IR — product revenues, net changed year-over-year?
- Collegium Pharmaceutical, Inc.'s nucynta IR — product revenues, net decreased by 45.8% year-over-year, from $26.5M to $14.36M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s nucynta IR — product revenues, net?
- Over 4 years (2021 to 2025), Collegium Pharmaceutical, Inc.'s nucynta IR — product revenues, net has grown at a 3.1% compound annual growth rate (CAGR), from $102.22M to $115.31M.
- What does nucynta IR — product revenues, net mean?
- This metric represents the total net revenue generated from the sale of the Nucynta IR product line after accounting for returns, discounts, rebates, and other sales-related adjustments. It serves as a key indicator of the product's market demand and commercial performance within the company's pain management portfolio. Monitoring this figure helps investors assess the revenue contribution and growth trajectory of this specific pharmaceutical asset.
Ask your AI about Collegium Pharmaceutical, Inc.'s nucynta ir — product revenues, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude